Molecular Testing Shapes Women’s Health Diagnostics
Clinicians and laboratory professionals now have access to broader clinical insights through molecular diagnostic techniques, which can detect antimicrobial resistance, spot pathogens overlooked by traditional testing, highlight the likelihood of cancer recurrence, and detail intricate tumor characteristics.
Two new studies relating to women’s health presented at the Association for Molecular Pathology 2026 Annual Meeting & Expo, taking place Nov. 10–14 in Seattle, showcase this information expansion. This research spans infectious disease diagnostics and oncology, illustrating a wide range of diagnostic growth.
Epigenetic Profiling Reveals Endometrial Cancer Risks
Another oncology study demonstrates how molecular profiling can reveal differences in recurrence risk and tumor biology that may not be apparent through conventional classification. At the University of California, San Francisco, investigators analyzed DNA methylation across 219 tumors to pinpoint patterns linked to the return of low-grade, limited-stage, copy number–low endometrioid adenocarcinoma, which is the most frequent form of endometrial cancer.
Data showed a spectrum of methylation changes strongly correlated with recurrence risk. Distinct methylation groupings also displayed varying frequencies of CTNNB1 and DICER1 mutations, alongside chromosome 1q copy number gains.
“Methylomic Stratification of Recurrence Risk in Primary, Low-Grade, Copy Number-Low Endometrioid Adenocarcinoma of the Uterus” was spearheaded by Matthew Zunitch from the University of California, San Francisco, who is scheduled to present his work during a poster session at 9:15 a.m. on Friday, Nov. 13, at the Seattle Convention Center.
Global endometrial cancer rates are high, with projections estimating 69,120 new cases and 13,860 deaths in the United States alone by 2025. Historically, Bokhman's classification divided endometrial cancer into Type I and Type II subtypes, but high heterogeneity limits its clinical utility.
The World Health Organization 5th edition classification categorizes endometrial carcinoma based on histological morphology, while next-generation sequencing has provided deeper insights into molecular profiles. A study analyzing 56 high-grade endometrial carcinoma cases found consensus on the predominant tumor subtype in only 62.5% of cases, with major diagnostic discrepancies observed in 35.8%.
Questions About Molecular Diagnostic Approaches
When does the Association for Molecular Pathology annual meeting take place?
The Association for Molecular Pathology 2026 Annual Meeting & Expo takes place Nov. 10–14 in Seattle.
How many tumors were profiled in the UCSF endometrial cancer study?
Researchers profiled DNA methylation in 219 tumors to identify patterns associated with recurrence risk in low-grade, copy number–low endometrioid adenocarcinoma.
Keep reading